Alertas Bibliograficas – Diabetes

Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
Pieber TR, Bode B, Mertens A, Cho YM, Christiansen E, Hertz CL, Wallenstein SOR, Buse JB, PIONEER 7 investigators.
Lancet Diabetes Endocrinol. 2019 Jul;7(7):528-539.

Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range.
Diabetes Care. 2019 Aug;42(8):1593-1603.

Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial.
Miras AD, Pérez-Pevida B, Aldhwayan M, Kamocka A, McGlone ER, Al-Najim W, et al.
Lancet Diabetes Endocrinol. 2019 Jul;7(7):549-559.

Intensive Glucose Control in Patients with Type 2 Diabetes — 15-Year Follow-up
Reaven, P,  Emanuele N, Wiitala, N et al  for the VADT Investigators
N Engl J Med 2019; 380:2215-2224

Diabetes Diagnosis and Control: Missed Opportunities to Improve Health
The 2018 Kelly West Award LectureCatherine C. Cowie
Diabetes Care 2019 Jun; 42(6): 994-1004

Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management
International Hypoglycaemia Study Group
Lancet Diabetes Endocrinol. 2019 May;7(5):385-396.

Prevalence and Prognosis of Unrecognized Myocardial Infarction in Asymptomatic Patients With Diabetes: A Two-Center Study With Up to 5 Years of Follow-up.
Elliott MD, Heitner JF, Kim H, Wu E, Parker MA, Lee DC, Kaufman DB, et al.
Diabetes Care. 2019 Apr 22. pii: dc182266.

Evidence‐based diabetes care for older people with Type 2 diabetes: a critical review
Sinclair AJ, Abdelhafiz, A, Forbes A, Munshi M
Diabetic  Medicin 2019 Abril:vol 36: (4): 399-413

The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study)
Laiteerapong N, Ham S, Gao Y, Howard H. Moffet, J, Elbert S and Karter A
Diabetes Care 2019 Mar; 42 (3): 416-426.

Interpretation of HbA1c in primary care and potential influence of anaemia and chronic kidney disease: an analysis from the Copenhagen Primary Care Laboratory (CopLab) Database
Borg R,Persson R, Siersma V, Lind B, Olivarius N, Andersen C

Management of Hyperglycemia in Type 2 Diabetes, 2018.
A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Davies M, D’Alessio,D Fradkin J et al
Diabetes Care 2018 Sep dci180033

Glycemic Control and Risk of Infections Among People With Type 1 or Type 2 Diabetes in a Large Primary Care Cohort Study.
Critchley JA, Carey IM, Harris T, DeWilde S, Hosking FJ, Cook DG.
Diabetes Care. 2018 Oct;41(10):2127-2135.

Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.
Stefan N, Häring HU, Cusi K.
Lancet Diabetes Endocrinol. 2018 Aug 30. pii: S2213-8587(18)30154-2.

Unique challenges of cystic fibrosis‐related diabetes
Bridges N,  Rowe R,  Holt H
Diabetic Medicine April 2018 : 35(9)1181-1188

Management of adults with diabetes on the haemodialysis unit: summary of guidance from the Joint British Diabetes Societies and the Renal Association
Frankl H, Kazempour‐Ardebili S, Bedi R, Chowdhury T, Nevine E , Gray S, Hardy D et al
Diabetic Medicin August 2018;35(8) 1018-1026

Type 2 diabetes in adolescents and young adults.
Lascar N, Brown J, Pattison H, Barnett A, Bailey C, Bellary S
The Lancet Diabetes & Endocrinology Published Online
August 25, 2017
Characteristics of people with high visit-to-visit glycaemic variability in Type 2 diabetes.
Noyes JD, Soto-Pedre E, Donnelly LA, Pearson ER.
Diabet Med. 2017 Jul 29. On line

Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study.
But A, De Bruin ML, Bazelier MT, Hjellvik V, Andersen M, Auvinen A et al.
Diabetologia. September 2017, Volume 60:1691–1703

Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial.
John R Petrie, Nishi Chaturvedi, Ian Ford, Martijn C G J Brouwers, Nicola Greenlaw, et al for the REMOVAL Study Group
Lancet Diabetes Endocrinol. 2017 Jun 9. pii: S2213-8587(17)30194-8.

Early prediction of autoimmune (type 1) diabetes
Simon E. Regnell and Åke Lernmark
Diabetologia. August 2017, Volume 60, Issue 8, pp 1370–1381

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal, Vlado Perkovic. et al  for the CANVAS Program Collaborative Group
NEJM 17:June 12

Early Glycemic Control and Magnitude of HbA1c Reduction Predict Cardiovascular Events and Mortality: Population-Based Cohort Study of 24,752 MetforminInitiators
Elisabeth Svensson, Lisbeth M. Baggesen et al
Diabetes Care 2017 Jun; 40 (6): 800-807

Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013.
Lipska K ,1 Yao X et al.
Diabetes Care 2017 Apr; 40 (4): 468-475.

Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial.
Pasquel, Francisco J et al.
The Lancet Diabetes & Endocrinology , Volume 5 , Issue 2 , 125 – 133.

Electrocardiographic Abnormalities and Cardiovascular Disease Risk in Type 1 Diabetes: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study Elsayed
Z. Soliman, Jye-Yu C. Backlund, Ionut Bebu, Trevor J. Orchard, Bernard Zinman and John M.Lachin
Diabetes Care 2017 Mar; dc162050.

Insulin analogues in type 1 diabetes mellitus: getting better all the time.
Nature Reviews Endocrinology
(2017) doi:10.1038/nrendo.2017.39 Published online 21 April 2017.

Relative effectiveness of insulin pump treatment over multiple daily injections and structured education during flexible intensive insulin treatment fortype 1 diabetes: cluster randomised trial (REPOSE)
BMJ 2017; 356 :j1285 BMJ. 2017 Mar 30;356:j1285.